The Cardiopulmonary segment at LivaNova focuses on developing and delivering advanced solutions for cardiac surgery and critical care. This includes a comprehensive range of oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and related products. Research and development efforts are directed towards improving the biocompatibility and performance of these devices to minimize patient trauma and enhance surgical outcomes. The segment's technologies are crucial for maintaining patient life support during complex cardiac procedures. By collaborating with perfusionists and surgeons, LivaNova aims to optimize perfusion strategies and improve patient recovery. Future opportunities include the development of miniaturized and integrated cardiopulmonary support systems.

LivaNova's Neuromodulation segment is dedicated to developing innovative therapies for neurological and psychiatric disorders. The primary product is the VNS Therapy System, an implantable device delivering vagus nerve stimulation for drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. Ongoing research explores the VITARIA System for heart failure treatment through VNS. The segment's R&D focuses on refining stimulation parameters, expanding therapeutic applications, and personalizing treatment protocols. Clinical trials and collaborations, such as the partnership with Verily, aim to identify clinical biomarkers and improve patient selection. The Neuromodulation segment is positioned to address unmet needs in neurological and psychiatric care, offering alternatives to traditional pharmacological interventions.